Major Depressive Disorder
📧 Sign up to get email alerts when something new happens for Major Depressive Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2021-09-21FDA Approved: ESCITALOPRAM ORAL SOLUTION — Supplemental Application (Chartwell RX, LLC)
FDA granted a supplemental approval for escitalopram oral solution from Chartwell RX, LLC under ANDA090477, adding an oral solution dosage f…
-
FDA approval · 2021-09-21FDA Approved: ESCITALOPRAM — Supplemental Application (Macleods Pharmaceuticals Limited)
FDA approved a supplemental application for escitalopram by Macleods Pharmaceuticals Limited.
-
FDA approval · 2021-09-21FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for venlafaxine hydrochloride from Teva Pharmaceuticals USA, Inc. The approval pertains to changes t…
-
FDA approval · 2021-09-21FDA Approved: CITALOPRAM — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for Citalopram from Hikma Pharmaceuticals USA, updating the generic product's labeling and/or manufa…
-
CLINICAL_TRIALS trial_result · 2021-09-21Clinical Trial Update: Connectivity Affecting the Antidepressant REsponse Study [Phase 4]
Phase 4 clinical trial assessing connectivity-related factors influencing antidepressant response in major depressive disorder has completed…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2021-09-21FDA Approved: FLUOXETINE — Supplemental Application (Torrent Pharmaceuticals Limited)
FDA approved a supplemental application for fluoxetine submitted by Torrent Pharmaceuticals Limited.
-
FDA label_change · 2021-09-21FDA Approved: FLUOXETINE — Supplemental Application (ScieGen Pharmaceuticals, Inc)
FDA approved a supplemental application for fluoxetine by ScieGen Pharmaceuticals to update the labeling for this generic antidepressant.
-
FDA approval · 2021-09-20FDA Approved: PRISTIQ EXTENDED-RELEASE — Supplemental Application (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.)
The FDA approved a supplemental application for Pristiq Extended-Release (desvenlafaxine succinate), expanding the product with an extended-…
-
FDA label_change · 2021-09-20FDA Approved: ZOLOFT — Supplemental Application (ROERIG)
FDA approved a supplemental application for Zoloft (sertraline hydrochloride) submitted by Roerig to update the product labeling.
-
FDA approval · 2021-09-20FDA Approved: CELEXA — Supplemental Application (Allergan, Inc.)
FDA approved a supplemental application for Celexa (citalopram) from Allergan, Inc.
-
FDA approval · 2021-09-20FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Dr. Reddy's Laboratories Limited)
FDA approved a supplemental application for venlafaxine hydrochloride from Dr. Reddy's Laboratories Limited.
-
FDA approval · 2021-09-20FDA Approved: ESCITALOPRAM OXALATE — Supplemental Application (Rising Pharma Holdings, Inc.)
The FDA approved a supplemental application for a generic escitalopram oxalate product from Rising Pharma Holdings, expanding access to this…
-
FDA label_change · 2021-09-20FDA Approved: DESVENLAFAXINE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA action on Sun Pharmaceutical's supplemental application for desvenlafaxine, likely updating labeling or expanding indications. The submi…
-
FDA approval · 2021-09-20FDA Approved: TRINTELLIX — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
The FDA approved a supplemental application for TRINTELLIX (vortioxetine) submitted by Takeda Pharmaceuticals America, Inc.
-
FDA approval · 2021-09-20FDA Approved: FLUOXETINE — Supplemental Application (Saptalis Pharmaceuticals, LLC.)
The FDA approved a supplemental application for fluoxetine from Saptalis Pharmaceuticals, LLC., enabling a generic fluoxetine product under …
-
FDA approval · 2021-09-20FDA Approved: FLUOXETINE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for fluoxetine from Aurobindo Pharma Limited, granting approval of a generic fluoxetine product.
-
FDA approval · 2021-09-20FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Vertical Pharmaceuticals, LLC)
The FDA approved a supplemental application for Venlafaxine hydrochloride from Vertical Pharmaceuticals, LLC.
-
FDA label_change · 2021-09-20FDA Approved: VENLAFAXINE — Supplemental Application (Alembic Pharmaceuticals Inc.)
FDA notice of a supplemental labeling application for VENLAFAXINE by Alembic Pharmaceuticals Inc.
-
FDA approval · 2021-09-20FDA Approved: FLUOXETINE HYDROCHLORIDE — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin Pharmaceuticals' supplemental application for fluoxetine hydrochloride, enabling marketing of a generic fluoxetine produc…
-
CLINICAL_TRIALS trial_result · 2021-09-16Clinical Trial Update: Adherence to Antidepressant Treatment in Subjects With Depression [Phase 2]
Phase 2 trial investigating adherence to antidepressant treatment in adults with depression; study terminated with results posted.
-
FDA approval · 2021-09-13FDA Approved: CITALOPRAM — Supplemental Application (Chartwell Governmental & Specialty RX, LLC.)
The FDA approved a supplemental application for citalopram filed by Chartwell Governmental & Specialty RX, LLC.
-
FDA approval · 2021-09-13FDA Approved: CITALOPRAM HYDROBROMIDE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for Aurobindo Pharma Limited's generic citalopram hydrobromide, expanding its approved product to ma…
-
CLINICAL_TRIALS trial_result · 2021-09-09Clinical Trial Update: Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors [Phase 3]
A Phase 3 trial evaluating methylphenidate to improve quality of life in patients undergoing radiation therapy for brain tumors has been ter…
-
CLINICAL_TRIALS trial_result · 2021-09-09Clinical Trial Update: Sertraline Compared With Hypericum Perforatum (St.John's Wort) in Treating Depression [Phase 3]
Phase 3 trial comparing sertraline to St. John’s wort for treatment of depression has completed.
-
FDA approval · 2021-09-08FDA Approved: ESCITALOPRAM ORAL SOLUTION — Supplemental Application (Chartwell RX, LLC)
FDA approved a supplemental application for escitalopram oral solution, adding an approved oral solution formulation for the antidepressant …